Alector, Inc. (ALEC): Total Liabilities
$262.59M
As of 2025-12-31
$212.82M
As of 2026-06-30
-22.9%
3-year compound annual growth
+3.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $262.59M | -23.1% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $341.50M | -30.0% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $487.67M | -14.9% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $573.21M | +11.5% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $513.93M | +132.8% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $220.72M | -2.8% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $227.17M | +16.4% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $195.24M | n/a | 2020-03-24, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Alector, Inc. (ALEC) | 2025-12-31 | $262.59M | -23.1% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $21.54M | +92.0% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $62.51M | -30.3% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $91.52M | n/m |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $54.27M | -42.0% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $576.73M | +101.9% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $62.17M | -22.3% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $104.17M | -16.2% |
Compare ALEC, LENZ, MGX, PTHS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗